Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 9/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 8/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 8/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 8/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niguldipine SCHEMBL245992 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL29615752 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL245993 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29385244 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29386264 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL3869443 | 0.99 | ADRA1A (0.98) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL9001404 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL467245 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL1228966 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL9386117 | 0.98 | ADRA1A (0.95) | ADRA1AADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117771378-A | Pharmaceutical composition for improving bioavailability of KRAS inhibitor and application thereof | 贝达药业股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4301370-A1 | COMBINATORY THERAPY FOR PREVENTING, INHIBITING, TREATING, OR REDUCING ANEURYSMS | The Regents of The University of California (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| CN-115474430-A | Composition for treatment and/or prevention of coronavirus infection | 弗劳恩霍夫应用研究促进协会 | 2022-12-13 | — | — | CN | claimed |
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| WO-2022187349-A1 | COMBINATORY THERAPY FOR PREVENTING, INHIBITING, TREATING, OR REDUCING ANEURYSMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| EP-0951280-B1 | HYDROPHILIC MICROPARTICLES AND METHODS TO PREPARE SAME | HERMES BIOSCIENCES INC (US) | 2004-01-14 | — | — | EP | claimed |
| EP-1232260-A2 | POLYMORPHISMS IN THE HUMAN MDR-1 GENE AND APPLICATIONS THEREOF | EPIDAUROS AG Biotechnologie Aktiengesellschaft (DE) | 2002-08-21 | — | — | EP | claimed |
| EP-0951280-A4 | HYDROPHILIC MICROPARTICLES AND METHODS TO PREPARE SAME | KIRPOTIN DMITRI (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2001009183-A2 | POLYMORPHISMS IN THE HUMAN MDR-1 GENE AND APPLICATIONS THEREOF | EPIDAUROS (DE) | 2001-02-08 | — | — | WO | claimed |
| US-6048550-A | Hydrophilic microparticles and methods to prepare same | UNIVERSITY TECHNOLOGY CORPORATION | 2000-04-11 | — | — | US | claimed |
| WO-1999062537-A9 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE AND INFLAMMATION INVOLVING MONOCYTE AND DENDRITIC CELL MEMBRANE PROTEINS | UNIV ROCKEFELLER (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1999062537-A1 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE AND INFLAMMATION INVOLVING MONOCYTE AND DENDRITIC CELL MEMBRANE PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0951280-A1 | HYDROPHILIC MICROPARTICLES AND METHODS TO PREPARE SAME | Kirpotin, Dmitri (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998014180-A1 | HYDROPHILIC MICROPARTICLES AND METHODS TO PREPARE SAME | KIRPOTIN DMITRI (US) | 1998-04-09 | — | — | WO | claimed |
| US-5514664-A | ANTITUMOR CHEMOTHERAPY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | ADRA1A 508/4885ADRA2A 351/4885ADRA2B 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.